FosterK.G., FingarD.C.. Mammalian target of rapamycin (mTOR):
conducting the cellular signaling symphony.J Biol Chem2010; 285(19):
14071–7. PMCID: 2863215.
2.
ShillingfordJ.M., PiontekK.B., GerminoG.G., WeimbsT.. Rapamycin ameliorates PKD resulting from
conditional inactivation of Pkd1.J Am Soc Nephrol2010; 21(3): 489–97.
PMCID: 2831854.
3.
TaoY., KimJ., SchrierR.W., EdelsteinC.L.. Rapamycin markedly slows disease
progression in a rat model of polycystic kidney disease.J Am Soc Nephrol2005; 16(1):
46–51.
4.
WahlP.R., SerraA.L., Le HirM., MolleK.D., HallM.N., WuthrichR.P.. Inhibition of mTOR with sirolimus slows
disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease
(ADPKD).Nephrol Dial Transplant2006. PMCID: 207.
5.
ZhangT., WangL., XiongX., MaoZ., MeiC.. Mycophenolate mofetil versus Rapamycin in
Han: SPRD rats with Polycystic Kidney Disease.Biol Res2009; 42(4):
437–44.
6.
WuM., WahlP.R., Le HirM., Wackerle-MenY., WuthrichR.P., SerraA.L.. Everolimus retards cyst growth and
preserves kidney function in a rodent model for polycystic kidney disease.Kidney Blood Press Res2007; 30(4):
253–9.
7.
ZafarI., BelibiF.A., HeZ., EdelsteinC.L.. Long-term rapamycin therapy in the Han:
SPRD rat model of polycystic kidney disease (PKD).Nephrol Dial Transplant2009; 24(8):
2349–53. PMCID: 2727300.
8.
ShillingfordJ.M., MurciaN.S., LarsonC.H., LowS.H., HedgepethR., BrownN.. The mTOR pathway is regulated by
polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney
disease.Proc Natl Acad Sci USA2006; 103(14):
5466–71. PMCID: 1459378.
9.
GattoneV.H.2nd, SindersR.M., HornbergerT.A., RohlingA.G.. Late progression of renal pathology and
cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.Kidney Int2009; 76(2):
178–82.
10.
WeiW., PopovV., WalochaJ.A., WenJ., Bello-ReussE.. Evidence of angiogenesis and
microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion
cast study.Kidney Int2006; 70(7):
1261–8.
11.
LiuP., ChengH., RobertsT.M., ZhaoJ.J.. Targeting the phosphoinositide 3-kinase
pathway in cancer.Nat Rev Drug Discov2009; 8(8):
627–44.
12.
KapoorA., FiglinR.A.. Targeted inhibition of mammalian target
of rapamycin for the treatment of advanced renal cell carcinoma.Cancer2009; 115(16):
3618–30.
13.
PericoN., AntigaL., CaroliA., RuggenentiP., FasoliniG., CafaroM.. Sirolimus therapy to halt the
progression of ADPKD.J Am Soc Nephrol2010; 21(6):
1031–40. PMCID: 2900967.
TorresV.E., BolettaA., ChapmanA., GattoneV., PeiY., QianQ.. Prospects for mTOR inhibitor use
in patients with polycystic kidney disease and hamartomatous diseases.Clin J Am Soc Nephrol2010; 5(7):
1312–29.
18.
SullivanL.P., WallaceD.P., GranthamJ.J.. Chloride and fluid secretion in
polycystic kidney disease.J Am Soc Nephrol1998; 9(5):
903–16.
19.
MasyukT.V., MasyukA.I., TorresV.E., HarrisP.C., LarussoN.E.. Octreotide inhibits hepatic
cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine
3’,5’-cyclic monophosphate.Gastroenterology2007; 132(3):
1104–16.
20.
van KeimpemaL., de ManR.A., DrenthJ.P.. Somatostatin analogues reduce liver
volume in polycystic liver disease.Gut2008; 57(9):
1338–9.
21.
RuggenentiP., RemuzziA., OndeiP., FasoliniG., AntigaL., Ene-IordacheB.. Safety and efficacy of long-acting
somatostatin treatment in autosomal-dominant polycystic kidney disease.Kidney Int2005; 68(1):
206–16.
22.
CaroliA., AntigaL., CafaroM., FasoliniG., RemuzziA., RemuzziG.. Reducing polycystic liver volume
in ADPKD: effects of somatostatin analogue octreotide.Clin J Am Soc Nephrol2010; 5(5): 783–9.
PMCID: 2863977.
23.
van KeimpemaL., NevensF., VanslembrouckR., van OijenM.G., HoffmannA.L., DekkerH.M.. Lanreotide reduces the volume of
polycystic liver: a randomized, double-blind, placebo-controlled trial.Gastroenterology2009; 137(5): 1661–8
e1–2.
24.
HoganM.C., MasyukT.V., PageL.J., KublyV.J., BergstralhE.J., LiX.. Randomized clinical trial of
long-acting somatostatin for autosomal dominant polycystic kidney and liver
disease.J Am Soc Nephrol2010; 21(6):
1052–61. PMCID: 2900957.
